HUTCHMED China vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

HUTCHMED China Ltd (0013.HK)

Q3 202625 Jun – 3 Sep 2026

▲4

HUTCHMED's pipeline wins and $1.3B GSK deal lift outlook

Fanregratinib hits pivotal trial goal, China filing accepted A late-stage trial of fanregratinib in bile-duct cancer met its main goal, with 42.5% of patients responding, and China's drug regulator accepted the filing with priority review. A new potential product moves closer to approval, which supports future revenue and the share price.
New clinical and regulatory milestone that adds a near-term product catalyst.
ORPATHYS approved for third China use in gastric cancer China approved ORPATHYS for a type of stomach cancer, its third approved use there. The drug is sold by partner AstraZeneca, so this widens an existing revenue stream and shows the pipeline keeps producing new labels, which is positive for the stock.
New regulatory approval that expands an already-marketed drug's sales base.
First-half oncology sales up 23%, cash pile strong Oncology revenue rose 23% to $162 million, with key drugs growing over 40%, and the company held $1.4 billion in cash while staying profitable. Solid sales and a strong balance sheet reduce financing risk and support the valuation.
New financial results showing the commercial business is growing and funded.
$1.3B GSK deal brings cash and outside validation GSK will pay $110 million upfront and up to about $1.3 billion total for rights outside China to an early cancer therapy. The cash funds research without dilution, and a major partner's backing signals the science is credible, both supportive for the shares.
New licensing deal that is the period's biggest capital and validation event.

July 202625 Jun – 3 Sep 2026

▲4

HUTCHMED's pipeline wins and $1.3B GSK deal lift outlook

Fanregratinib hits pivotal trial goal, China filing accepted A late-stage trial of fanregratinib in bile-duct cancer met its main goal, with 42.5% of patients responding, and China's drug regulator accepted the filing with priority review. A new potential product moves closer to approval, which supports future revenue and the share price.
New clinical and regulatory milestone that adds a near-term product catalyst.
ORPATHYS approved for third China use in gastric cancer China approved ORPATHYS for a type of stomach cancer, its third approved use there. The drug is sold by partner AstraZeneca, so this widens an existing revenue stream and shows the pipeline keeps producing new labels, which is positive for the stock.
New regulatory approval that expands an already-marketed drug's sales base.
First-half oncology sales up 23%, cash pile strong Oncology revenue rose 23% to $162 million, with key drugs growing over 40%, and the company held $1.4 billion in cash while staying profitable. Solid sales and a strong balance sheet reduce financing risk and support the valuation.
New financial results showing the commercial business is growing and funded.
$1.3B GSK deal brings cash and outside validation GSK will pay $110 million upfront and up to about $1.3 billion total for rights outside China to an early cancer therapy. The cash funds research without dilution, and a major partner's backing signals the science is credible, both supportive for the shares.
New licensing deal that is the period's biggest capital and validation event.

Latest25 Jun – 3 Sep 2026

▲4

HUTCHMED's pipeline wins and $1.3B GSK deal lift outlook

Fanregratinib hits pivotal trial goal, China filing accepted A late-stage trial of fanregratinib in bile-duct cancer met its main goal, with 42.5% of patients responding, and China's drug regulator accepted the filing with priority review. A new potential product moves closer to approval, which supports future revenue and the share price.
New clinical and regulatory milestone that adds a near-term product catalyst.
ORPATHYS approved for third China use in gastric cancer China approved ORPATHYS for a type of stomach cancer, its third approved use there. The drug is sold by partner AstraZeneca, so this widens an existing revenue stream and shows the pipeline keeps producing new labels, which is positive for the stock.
New regulatory approval that expands an already-marketed drug's sales base.
First-half oncology sales up 23%, cash pile strong Oncology revenue rose 23% to $162 million, with key drugs growing over 40%, and the company held $1.4 billion in cash while staying profitable. Solid sales and a strong balance sheet reduce financing risk and support the valuation.
New financial results showing the commercial business is growing and funded.
$1.3B GSK deal brings cash and outside validation GSK will pay $110 million upfront and up to about $1.3 billion total for rights outside China to an early cancer therapy. The cash funds research without dilution, and a major partner's backing signals the science is credible, both supportive for the shares.
New licensing deal that is the period's biggest capital and validation event.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.